Changes in Nursing Burden Following Memantine for Agitation and Aggression in Long-Term Care Residents with Moderate to Severe Alzheimer’s Disease: An Open-Label Pilot Study

• Published in: CNS drugs 2011-05, Vol.25 (5), p.425-433
• Main Authors: Herrmann, Nathan, Cappell, Jaclyn, Eryavec, Goran M., Lanctôt, Krista L.
• Format: Article
• Language: English
• Subjects: Adult and adolescent clinical studies; Aggression - drug effects; Aggression - psychology; Alzheimer Disease - complications; Alzheimer Disease - drug therapy; Alzheimer Disease - nursing; Alzheimer Disease - psychology; Alzheimer's disease; Biological and medical sciences; Care and treatment; Caregivers - psychology; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases; Dopamine Agents - adverse effects; Dopamine Agents - therapeutic use; Female; Health aspects; Humans; Long-Term Care; Long-term care of the sick; Male; Medical sciences; Medicine; Medicine & Public Health; Memantine - adverse effects; Memantine - therapeutic use; Mental Disorders - complications; Mental Disorders - drug therapy; Neurology; Neuropharmacology; Neurosciences; Nursing Homes; Organic mental disorders. Neuropsychology; Original Research Article; Pharmacology. Drug treatments; Pharmacotherapy; Pilot Projects; Psychiatric patients; Psychiatry; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease); Psychology. Psychoanalysis. Psychiatry; Psychomotor Agitation - complications; Psychomotor Agitation - drug therapy; Psychomotor Agitation - psychology; Psychopathology. Psychiatry; Psychopharmacology; Treatment Outcome
• ISSN: 1172-7047; 1179-1934
• DOI: 10.2165/11588160-000000000-00000

Background : Agitation and aggression are common neuropsychiatric symptoms of Alzheimer’s disease (AD) with a negative impact on caregivers. Objective : The aim of the study was to determine whether changes in agitation and aggression would follow memantine treatment and, if so, be associated with changes in nursing burden in institutionalized patients with moderate to severe AD. Study Design : This was a 3-month open-label trial of memantine. Setting : The setting was two long-term care facilities. Patients : Thirty-one institutionalized patients with moderate to severe AD and significant behavioural and psychiatric symptoms were included in the study. Intervention : Memantine was titrated to a target dose of 10mg twice daily. Main Outcome Measure : Effectiveness was assessed by the change in the Neuropsychiatric Inventory-Nursing Home (NPI-NH) agitation/aggression subscale and Clinical Global Impression of Change (CGI-C) scale using the intent-to-treat population. To establish caregiver impact, the effect on nursing burden was measured by the Modified Nursing Care Assessment Scale (primary outcome). As a secondary analysis, the caregiver distress subscale of the NPI-NH was examined, as well as changes in as required ( pro re nata [prn]) psychotropic medication use. Results : Twenty-four patients completed the study. A significant decrease in agitation and aggression (F-test with 3 and 90 degrees of freedom [F 3.90 ] = 3.721, p = 0.014) was demonstrated following memantine, with 48% of patients improving (either much improved or minimally improved) on the CGI-C scale. In addition, nursing burden (t-test with 30 degrees of freedom [t 30 ] = 3.02, p = 0.005), caregiver distress (F 3.90 = 4.125, p = 0.009) and the use of prn psychotropics decreased following memantine treatment (Z = −1.99, p = 0.046). Fourteen patients experienced at least one adverse event during memantine treatment. The most common adverse event associated with treatment was somnolence (n = 5). Conclusion : The results of this study suggest that the decreased agitated and aggressive behaviour in institutionalized patients with moderate to severe AD following treatment with memantine was accompanied by improvements in nursing burden and decreased psychotropic use. These findings should be confirmed in a larger, controlled trial. ClinicalTrials.gov Identifier: NCT00401167